nVerses Capital LLC Buys Shares of 3,100 Pulmonx Co. (NASDAQ:LUNG)

nVerses Capital LLC purchased a new position in shares of Pulmonx Co. (NASDAQ:LUNG) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,100 shares of the company’s stock, valued at approximately $26,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Squarepoint Ops LLC increased its position in Pulmonx by 261.2% during the second quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after buying an additional 104,432 shares in the last quarter. Sei Investments Co. increased its position in Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after purchasing an additional 1,800 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Pulmonx by 7.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock valued at $6,714,000 after purchasing an additional 69,595 shares during the last quarter. XTX Topco Ltd purchased a new position in Pulmonx in the 2nd quarter valued at about $222,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Pulmonx by 13.1% during the 2nd quarter. Renaissance Technologies LLC now owns 301,410 shares of the company’s stock worth $1,911,000 after purchasing an additional 34,800 shares during the last quarter. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on LUNG. Canaccord Genuity Group boosted their price objective on shares of Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company cut their price target on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Insider Transactions at Pulmonx

In other Pulmonx news, CEO Steven S. Williamson purchased 14,245 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average price of $6.84 per share, for a total transaction of $97,435.80. Following the completion of the acquisition, the chief executive officer now owns 219,531 shares of the company’s stock, valued at approximately $1,501,592.04. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the completion of the sale, the director now owns 1,111,974 shares in the company, valued at approximately $8,995,869.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven S. Williamson purchased 14,245 shares of Pulmonx stock in a transaction that occurred on Tuesday, August 20th. The shares were bought at an average cost of $6.84 per share, for a total transaction of $97,435.80. Following the completion of the transaction, the chief executive officer now directly owns 219,531 shares in the company, valued at $1,501,592.04. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 50,351 shares of company stock worth $361,494. 5.70% of the stock is currently owned by company insiders.

Pulmonx Price Performance

Pulmonx stock opened at $6.13 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.92 and a current ratio of 8.97. The company has a market cap of $237.94 million, a price-to-earnings ratio of -3.98 and a beta of 0.64. Pulmonx Co. has a 1 year low of $5.46 and a 1 year high of $14.84. The firm has a 50 day moving average price of $7.31 and a 200 day moving average price of $7.34.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. The firm had revenue of $20.78 million for the quarter, compared to analysts’ expectations of $20.23 million. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. Sell-side analysts predict that Pulmonx Co. will post -1.64 earnings per share for the current year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.